ADAR1 Capital Management LLC Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

ADAR1 Capital Management LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,900 shares of the biopharmaceutical company's stock, valued at approximately $682,000.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Larson Financial Group LLC grew its stake in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Versant Capital Management Inc raised its position in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Alnylam Pharmaceuticals by 1,754.5% in the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 193 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 5.1 %

Shares of NASDAQ:ALNY traded up $11.49 during trading on Friday, reaching $237.77. 1,577,336 shares of the stock traded hands, compared to its average volume of 863,403. The stock has a market cap of $30.93 billion, a P/E ratio of -109.57 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a 50-day moving average of $253.20 and a two-hundred day moving average of $258.37. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Remove Ads

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ALNY. HC Wainwright reiterated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Sanford C. Bernstein dropped their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 over the last 90 days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.